Strong electron microscopy growth and strategic buyouts are likely to drive Thermo Fisher Scientific's (TMO) growth. Yet, macroeconomic issues and currency fluctuations continue to dampen business growth. The stock carries a Zacks Rank #3 (Hold) currently. Factors Driving Growth for TMO Stock Within the pharma and biotech end market, of late, Thermo Fisher's biosciences and bioproduction businesses have significantly expanded their capacity to meet the global vaccine manufacturing requirements. The pharma s ...

Thermo Fisher Scientific's (TMO) PPD clinical research business has expanded its global laboratory services by opening a new bioanalytical lab in GoCo Health Innovation City in Gothenburg, Sweden. The 29,000- square-foot facility will serve pharmaceutical and biotech customers with advanced laboratory services and cutting-edge instrumentation across all phases of pharmaceutical development to help deliver life-changing medicines to patients worldwide. The latest development furthers the company's strategy t ...

Biognosys' Spectronaut®, the leading vendor-agnostic software for DIA proteomics, is now directly available from Thermo Fisher Scientific under a reselling agreement End users can get access to Thermo Scientific mass spectrometry systems and Biognosys' Spectronaut software via a single offer issued by Thermo Fisher Thermo Fisher will directly quote and sell Biognosys' Spectronaut software from its product catalog ZURICH and NEWTON, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Biognosys, a leading inventor and ...

Thermo Fisher Scientific (NYSE:TMO) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 8:30 AM ET Company Participants Marc Casper - Chairman, President and CEO Conference Call Participants Tejas Savant - Morgan Stanley Tejas Savant Hey, everyone. Good morning. I'm Tejas Savant. I cover life sciences here at Morgan Stanley. Before we kick it off, for important disclosures, please see the Morgan Stanley Research disclosure website at morganstanley.com/researchdisclosures. And if you ha ...

Thermo Fisher Scientific Inc. (TMO) is gaining investors' confidence due to its impressive partnerships. Of late, the company has launched a slew of products to enhance its portfolio. However, declining COVID-19 testing-related demand, as well as adverse macroeconomic impacts might deter Thermo Fisher's growth. Year to date, this Zacks Rank #3 (Hold) company's shares have rallied 15.7% compared with 7.8% growth of the industry. The S&P 500 composite has risen 17.6% during the said time frame. The renowned m ...

isak55/iStock via Getty Images Introduction Thermo Fisher Scientific Inc (TMO) Total Return SPDR® S&P 500® ETF Trust (SPY) Total Return 229.33 The Health Care Select Sector SPDR® ETF (XLV) Total Return 0.00% -200.0% 2016 2018 2020 2022 2024 Seeking AlphaQ Jul 27, 2024, 5:05 AM EDT Po esed by YCHARTS Data by YCharts A Future-Proof Business Model Not only does the healthcare sector come with anti-cyclical demand and secular growth, but it also helps to improve the lives of countless people. Before the Industi ...

Thermo Fisher Scientific (NYSE:TMO) stock has done little since my last quarterly review, down about 2% including the bounce it got after reporting 2Q 2024 earnings. The downgrade to Hold in my last article has been a good call so far. | --- | --- | --- | --- | --- | --- | |-------|------------------------------------------|-------|----------------------------------------|-------|----------------------------------------------| | | Thermo Fisher Organic Sales Growth Rates | | Company Life Sciences Analytical ...

Thermo Fisher Scientific Inc.'s (TMO) second-quarter 2024 adjusted earnings per share (EPS) of $5.37 topped the Zacks Consensus Estimate by 4.9%. The figure also rose 4.3% year over year. GAAP EPS was $4.04, up 15.1% on a year-over-year basis. Segment Details Revenues in the Life Sciences Solutions segment (22.3% of total revenues) declined 4.4% year over year to $2.36 billion, while Analytical Instruments Segment sales (16.9%) rose 1.9% to $1.78 billion. Our model projected revenues of $2.26 billion for th ...

Marc Casper Marc Casper Operator Conference Call Participants Raf, thank you. Good morning, everyone and thanks for joining us today for our second quarter call. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. This quarter we also launched products to help our custo ...

The reported revenue represents a surprise of +0.29% over the Zacks Consensus Estimate of $10.51 billion. With the consensus EPS estimate being $5.13, the EPS surprise was +4.68%. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Revenue Growth - Organic: -1% compared to the -1.6% average estimate based on five analysts. Revenues- Labo ...